Study of the efficacy and safety of Mexidol forte 250 consecutive using in patients with chronic cerebral ischemia caused by hypertension and atherosclerosis

Abstract

Objective: To analyze the efficacy and safety of Mexidol consecutive using in patients with chronic cerebral ischemia (CCI) caused by hypertension and atherosclerosis. Material and methods: We stadied 23 patients with CCI who received Mexidol in dose 500 mg a day during 14 days by introvenal introduction with the followind peroral administration in doses 250 mg three times a day during 60 days. A comparison group included 25 patients with CCI matched for age, risk factors and severity of neurological symptoms, who did not receive Mexidol. Patients of both groups received standard treatment that included medications needed for the complete correction of the risk factors. Assessment tools: Clinical Global Impression scale, МоСа scale, MFI 20 scale, anxiety and depression Hamilton scale, Tinetti scale. Results: To the end of the stady (74-th day), a decrease in the severity of psycho-emotional disorders, asthenia, improvement of the general overall physical activity were identified in patients of the main group compared to these of the comparison group. Conclusion: The high efficacy and safety of treatment of CCI patients with Mexidol using.